Evidence map›Paper›PMID 25258665›Full record

ReviewWorld journal of stem cells2014

Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?

Christen L Walters Haygood, Rebecca C Arend, J Michael Straughn, Donald J Buchsbaum

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of stem cells, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed.

  1. Article
  2. Article
  3. The biological roles of CD47 in ovarian cancer progression.Cancer immunology, immunotherapy : CII · 2024
    Review
  4. AhRR and PPP1R3C: Potential Prognostic Biomarkers for Serous Ovarian Cancer.International journal of molecular sciences · 2023
    Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Ovarian cancer stem cells: ready for prime time?Archives of gynecology and obstetrics · 2020
    Review
  12. Review
  13. B7-H3-targeted Radioimmunotherapy of Human Cancer.Current medicinal chemistry · 2020
    Review
  14. Ovarian cancer stem cells and targeted therapy.Journal of ovarian research · 2019
    Review
  15. Article
  16. Targeting Ovarian Cancer Cell Cytotoxic Drug Resistance Phenotype withEvidence-based complementary and alternative medicine : eCAM · 2019
    Article
  17. Article
  18. The role of Notch signaling in the mammalian ovary.Reproduction (Cambridge, England) · 2017
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Christen L Walters HaygoodChristen L Walters Haygood, Rebecca C Arend, J Michael Straughn, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35233, United States.
Rebecca C ArendChristen L Walters Haygood, Rebecca C Arend, J Michael Straughn, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35233, United States.
J Michael StraughnChristen L Walters Haygood, Rebecca C Arend, J Michael Straughn, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35233, United States.
Donald J BuchsbaumChristen L Walters Haygood, Rebecca C Arend, J Michael Straughn, Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, AL 35233, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite significant effort and research funds, epithelial ovarian cancer remains a very deadly disease. There are no effective screening methods that discover early stage disease; the majority of patients are diagnosed with advanced disease. Treatment modalities consist primarily of radical debulking surgery followed by taxane and platinum-based chemotherapy. Newer therapies including limited targeted agents and intraperitoneal delivery of chemotherapeutic drugs have improved disease-free intervals, but failed to yield long-lasting cures in most patients. Chemotherapeutic resistance, particularly in the recurrent setting, plagues the disease. Targeting the pathways and mechanisms behind the development of chemoresistance in ovarian cancer could lead to significant improvement in patient outcomes. In many malignancies, including blood and other solid tumors, there is a subgroup of tumor cells, separate from the bulk population, called cancer stem cells (CSCs). These CSCs are thought to be the cause of metastasis, recurrence and resistance. However, to date, ovarian CSCs have been difficult to identify, isolate, and target. It is felt by many investigators that finding a putative ovarian CSC and a chemotherapeutic agent to target it could be the key to a cure for this deadly disease. This review will focus on recent advances in this arena and discuss some of the controversies surrounding the concept.

Indexed as

Cancer stem cellsChemoresistanceChemotherapyEpithelial ovarian cancerRecurrent ovarian cancerTargeted therapy

Identifiers

PMID25258665
PMCPMC4172672

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.